Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | Chief Development Officer | December 24, 2024 | December 27, 2024 |
| MyoKardia, Inc.MYOK · Entity 145206 | Chief Medical Officer | February 08, 2019 | February 12, 2019 |
| PROKIDNEY CORP.DNAC · Entity 5181 | Director | June 29, 2021 | June 30, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edgewise Therapeutics, Inc.
Report date December 24, 2024 · Filed December 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,425 |
Reported balance
After 2024-12-24 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-12-24 · Exercise / conversion · Acquired 29,709 · Balance 36,425 F1: Includes 2,187 shares purchased on November 15, 2023, 2,254 shares purchased on May 15, 2024 and 2,275 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 8,445 |
Reported balance
After 2024-12-24 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-12-24 · Sale · Disposed 27,980 · Balance 8,445 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2024. F3: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $30.02, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 6,716 |
Reported balance
After 2024-12-24 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-12-24 · Sale · Disposed 1,729 · Balance 6,716 F4: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.03 to $30.13, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.94 · Expires 2032-12-30 | Direct | 270,291 |
Reported balance
After 2024-12-24 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-12-24 · Exercise / conversion · Disposed 29,709 · Balance 270,291 F5: 1/4th of the shares subject to the option became vested and exercisable on December 19, 2023 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 2,187 shares purchased on November 15, 2023, 2,254 shares purchased on May 15, 2024 and 2,275 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2024.
F3: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $30.02, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.03 to $30.13, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: 1/4th of the shares subject to the option became vested and exercisable on December 19, 2023 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.
MyoKardia, Inc.
Report date February 08, 2019 · Filed February 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.11 · Expires 2029-02-07 | Direct | 24,900 |
Reported balance
After 2019-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-08 · Grant · Acquired 24,900 · Balance 24,900 F1: The shares underlying the option vest in 48 equal monthly installments from January 1, 2019, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,500 |
Reported balance
After 2019-02-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-08 · Grant · Acquired 8,500 · Balance 8,500 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option vest in 48 equal monthly installments from January 1, 2019, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer.
PROKIDNEY CORP.
Report date June 29, 2021 · Filed June 30, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-06-29 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256725) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256725) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Renovacor, Inc.
Report date December 01, 2022 · Filed December 05, 2022
Section 16 reporting ended · disclosed 2022-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-12-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-12-01 · Disposition to issuer · Disposed 17,425 · Balance 0 F1: Represents shares of common stock underlying Company Time-Vesting RSUs (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")). Each unvested RSU outstanding immediately prior to the First Effective Time (as defined in the Merger Agreement) was accelerated, cancelled and converted into the right to receive a number of Rocket common stock, rounded to the nearest whole number, equal to the number of shares of Issuer common stock underlying such Company Time-Vesting RSU multiplied by the Exchange Ratio (as defined in the Merger Agreement). Row 2 · 2022-12-01 · Grant · Acquired 35,226 · Balance 35,226 F2: Represents shares of common stock underlying restricted stock units granted pursuant to that certain Agreement and Plan of Merger, dated as of March 22, 2021, by and among the Issuer, Renovacor Holdings, Inc. and CHAQ 2 Merger Sub, Inc. (the "SPAC Merger Agreement") as Earnout RSU Awards (as defined in the SPAC Merger Agreement). Pursuant to the terms of the SPAC Merger Agreement, the Earnout RSU Awards have fully vested upon the consummation of the merger. Row 3 · 2022-12-01 · Disposition to issuer · Disposed 35,226 · Balance 0 F3: The shares underlying the Earnout RSU Awards were cancelled and converted into the right to receive the Per Share Merger Consideration (as defined in the Merger Agreement). 1,822 shares of Rocket common stock were withheld to satisfy applicable withholding taxes upon vesting of restricted stock units. |
| Stock OptionSEC Table II · derivative / convertible security · Expires 2031-06-01 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-12-01 · Disposition to issuer · Disposed 88,991 · Balance 0 F4: Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F5: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. |
| Stock OptionSEC Table II · derivative / convertible security · Expires 2031-09-03 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-12-01 · Disposition to issuer · Disposed 169,849 · Balance 0 F4: Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F5: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. |
| Stock OptionSEC Table II · derivative / convertible security · Expires 2032-01-24 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-12-01 · Disposition to issuer · Disposed 34,850 · Balance 0 F4: Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F5: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying Company Time-Vesting RSUs (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")). Each unvested RSU outstanding immediately prior to the First Effective Time (as defined in the Merger Agreement) was accelerated, cancelled and converted into the right to receive a number of Rocket common stock, rounded to the nearest whole number, equal to the number of shares of Issuer common stock underlying such Company Time-Vesting RSU multiplied by the Exchange Ratio (as defined in the Merger Agreement).
F2: Represents shares of common stock underlying restricted stock units granted pursuant to that certain Agreement and Plan of Merger, dated as of March 22, 2021, by and among the Issuer, Renovacor Holdings, Inc. and CHAQ 2 Merger Sub, Inc. (the "SPAC Merger Agreement") as Earnout RSU Awards (as defined in the SPAC Merger Agreement). Pursuant to the terms of the SPAC Merger Agreement, the Earnout RSU Awards have fully vested upon the consummation of the merger.
F3: The shares underlying the Earnout RSU Awards were cancelled and converted into the right to receive the Per Share Merger Consideration (as defined in the Merger Agreement). 1,822 shares of Rocket common stock were withheld to satisfy applicable withholding taxes upon vesting of restricted stock units.
F4: Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent.
F5: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 24, 2024 Filed Dec 27, 2024 21:30 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 29,709 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001562180-24-008599 · primarydocument.xml · derivative · entry 4 Semigran Marc · CIK 0001691494 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 270,291 Underlying: Common Stock · 29,709 shares Expires 2032-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4th of the shares subject to the option became vested and exercisable on December 19, 2023 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| December 24, 2024 Filed Dec 27, 2024 21:30 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,729 | $30.08 | $52,008.84 |
DisclosureSEC source: 0001562180-24-008599 · primarydocument.xml · nonDerivative · entry 3 Semigran Marc · CIK 0001691494 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,716 F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.03 to $30.13, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 24, 2024 Filed Dec 27, 2024 21:30 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 27,980 | $29.66 | $829,906.39 |
DisclosureSEC source: 0001562180-24-008599 · primarydocument.xml · nonDerivative · entry 2 Semigran Marc · CIK 0001691494 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,445 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2024. F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $30.02, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 24, 2024 Filed Dec 27, 2024 21:30 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 29,709 | $8.94 | $265,598.46 |
DisclosureSEC source: 0001562180-24-008599 · primarydocument.xml · nonDerivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,187 shares purchased on November 15, 2023, 2,254 shares purchased on May 15, 2024 and 2,275 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:15 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 23,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-006262 · primarydocument.xml · derivative · entry 2 Semigran Marc · CIK 0001691494 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,125 Underlying: Common Stock · 23,125 shares Expires 2034-08-12 F2 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2024. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:15 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 138,750 | $0.00 Strike: $17.05 | $0.00 |
DisclosureSEC source: 0001562180-24-006262 · primarydocument.xml · derivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,750 Underlying: Common Stock · 138,750 shares Expires 2034-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on August 12, 2024, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 23:13 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 133,333 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001562180-23-006453 · primarydocument.xml · derivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,333 Underlying: Common Stock · 133,333 shares Expires 2033-08-17 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| December 30, 2022 Filed Jan 3, 2023 21:44 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001562180-23-000045 · primarydocument.xml · derivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-12-30 F1 · derivative.exercise_date: 1/4th of the shares subject to the option become vested and exercisable on December 19, 2023 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:21 UTC | Renovacor, Inc. RCOR · Entity 114644 | Disposition to issuerStock Option · Derivative | 34,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-023381 · form4.xml · derivative · entry 6 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,850 shares Expires 2032-01-24 F4 · derivative.exercise_price: Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F5 · derivative.exercise_date: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:21 UTC | Renovacor, Inc. RCOR · Entity 114644 | Disposition to issuerStock Option · Derivative | 169,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-023381 · form4.xml · derivative · entry 5 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 169,849 shares Expires 2031-09-03 F4 · derivative.exercise_price: Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F5 · derivative.exercise_date: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:21 UTC | Renovacor, Inc. RCOR · Entity 114644 | Disposition to issuerStock Option · Derivative | 88,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-023381 · form4.xml · derivative · entry 4 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 88,991 shares Expires 2031-06-01 F4 · derivative.exercise_price: Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F5 · derivative.exercise_date: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:21 UTC | Renovacor, Inc. RCOR · Entity 114644 | Disposition to issuerCommon Stock | 35,226 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-023381 · form4.xml · nonDerivative · entry 3 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: The shares underlying the Earnout RSU Awards were cancelled and converted into the right to receive the Per Share Merger Consideration (as defined in the Merger Agreement). 1,822 shares of Rocket common stock were withheld to satisfy applicable withholding taxes upon vesting of restricted stock units. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:21 UTC | Renovacor, Inc. RCOR · Entity 114644 | GrantCommon Stock | 35,226 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-023381 · form4.xml · nonDerivative · entry 2 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,226 F2 · price: Represents shares of common stock underlying restricted stock units granted pursuant to that certain Agreement and Plan of Merger, dated as of March 22, 2021, by and among the Issuer, Renovacor Holdings, Inc. and CHAQ 2 Merger Sub, Inc. (the "SPAC Merger Agreement") as Earnout RSU Awards (as defined in the SPAC Merger Agreement). Pursuant to the terms of the SPAC Merger Agreement, the Earnout RSU Awards have fully vested upon the consummation of the merger. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 21:21 UTC | Renovacor, Inc. RCOR · Entity 114644 | Disposition to issuerCommon Stock | 17,425 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-023381 · form4.xml · nonDerivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Represents shares of common stock underlying Company Time-Vesting RSUs (as defined in the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement")). Each unvested RSU outstanding immediately prior to the First Effective Time (as defined in the Merger Agreement) was accelerated, cancelled and converted into the right to receive a number of Rocket common stock, rounded to the nearest whole number, equal to the number of shares of Issuer common stock underlying such Company Time-Vesting RSU multiplied by the Exchange Ratio (as defined in the Merger Agreement). Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 18:30 UTC | Renovacor, Inc. RCOR · Entity 114644 | GrantStock Option · Derivative | 34,850 | $0.00 Strike: $6.45 | $0.00 |
DisclosureSEC source: 0000899243-22-003302 · doc4.xml · derivative · entry 2 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,850 Underlying: Common Stock · 34,850 shares Expires 2032-01-24 F2 · derivative.exercise_date: The stock option will vest and become exercisable in full on January 24, 2026, with 25% vesting on January 24, 2023, and the remainder vesting in equal monthly installments on the24th of each month for the remaining 36months, subject to the continuous service of the Reporting Person on such vesting date. Read SEC document |
| January 24, 2022 Filed Jan 26, 2022 18:30 UTC | Renovacor, Inc. RCOR · Entity 114644 | GrantCommon Stock | 17,425 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-003302 · doc4.xml · nonDerivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,651 F1 · shares: These restricted stock units will vest in four equal annual installments beginning on January 24, 2023, subject to continued service with the Company. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 16:30 UTC | Renovacor, Inc. RCOR · Entity 114644 | GrantStock Option · Derivative | 88,991 | $0.00 Strike: $10.83 | $0.00 |
DisclosureSEC source: 0000899243-21-049395 · doc4.xml · derivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,991 Underlying: Common Stock · 88,991 shares Expires 2031-06-01 F1 · derivative.exercise_date: On September 2, 2021, the Reporting Person was granted a stock option that will vest and become exercisable in full on December 2, 2021, subject to the achievement of certain performance based milestones set forth in the Employment Agreement by and between the Issuer and the Reporting Person, dated May 5, 2021 (with the achievement of such performance based milestones subject to the approval of the Compensation Committee of the Board of Directors of the Issuer), and the continuous service of the Reporting Person on such vesting date. On December 20, 2021, the Compensation Committee of the Board of Directors of the Issuer determined that the performance criteria was met, resulting in the vesting of the option as to 88,991 shares as of such vesting date. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 18:59 UTC | Renovacor, Inc. RCOR · Entity 114644 | GrantOption · Derivative | 169,849 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001192482-21-000710 · edgar.xml · derivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,849 Underlying: Common Stock · 169,849 shares Expires 2031-09-03 F1 · derivative.exercise_date: The stock option will vest and become exercisable in full on September 3, 2025, with 25% vesting on September 3, 2022, and the remainder vesting in equal monthly installments on the 3rd of each month for the remaining 36 months, subject to the continuous service of the Reporting Person on such vesting date. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 16:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantRestricted Stock Units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-003299 · doc4.xml · derivative · entry 2 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 16:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 24,900 | $0.00 Strike: $40.11 | $0.00 |
DisclosureSEC source: 0000899243-19-003299 · doc4.xml · derivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,900 Underlying: Common Stock · 24,900 shares Expires 2029-02-07 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2019, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:32 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Tax withholdingCommon Stock | 517 | $44.26 | $22,879.94 |
DisclosureSEC source: 0000899243-19-000911 · doc4.xml · nonDerivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,110 Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:57 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionRestricted Stock Units · Derivative | 1,325 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000408 · doc4.xml · derivative · entry 2 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,975 Underlying: Common Stock · 1,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:57 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 1,325 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-000408 · doc4.xml · nonDerivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 31, 2018 Filed Dec 20, 2018 21:23 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantCommon Stock | 302 | $42.16 | $12,732.32 |
DisclosureSEC source: 0000899243-18-031518 · doc4.xml · nonDerivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan. Read SEC document |
| September 05, 2018 Filed Sep 6, 2018 17:00 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,600 | $0.00 Strike: $15.95 | $0.00 |
DisclosureSEC source: 0000899243-18-023935 · doc4.xml · derivative · entry 6 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 3,600 shares Expires 2026-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on December 1, 2017 and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| September 05, 2018 Filed Sep 6, 2018 17:00 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 3,600 | $60.00 | $216,000.00 |
DisclosureSEC source: 0000899243-18-023935 · doc4.xml · nonDerivative · entry 4 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 05, 2018 Filed Sep 6, 2018 17:00 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 3,600 | $15.95 | $57,420.00 |
DisclosureSEC source: 0000899243-18-023935 · doc4.xml · nonDerivative · entry 3 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 17:00 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 41,400 | $0.00 Strike: $15.95 | $0.00 |
DisclosureSEC source: 0000899243-18-023935 · doc4.xml · derivative · entry 5 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,600 Underlying: Common Stock · 41,400 shares Expires 2026-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on December 1, 2017 and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 17:00 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 41,400 | $59.49 | $2,463,006.06 |
DisclosureSEC source: 0000899243-18-023935 · doc4.xml · nonDerivative · entry 2 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 17:00 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 41,400 | $15.95 | $660,330.00 |
DisclosureSEC source: 0000899243-18-023935 · doc4.xml · nonDerivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 17:45 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $15.95 | $0.00 |
DisclosureSEC source: 0000899243-18-018747 · doc4.xml · derivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2026-11-30 F1 · balance_after: On December 1, 2016, the Reporting Person was granted an option to purchase 25,000 shares of Common Stock under the issuer's 2015 Equity Incentive Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the issuer's securities. On June 28, 2018, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 6,250 of the shares underlying such option. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 19:51 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantRestricted Stock Units · Derivative | 5,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001373 · doc4.xml · derivative · entry 2 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 19:51 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 31,800 | $0.00 Strike: $52.00 | $0.00 |
DisclosureSEC source: 0000899243-18-001373 · doc4.xml · derivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,800 Underlying: Common Stock · 31,800 shares Expires 2028-01-15 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2018, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 15:58 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $15.95 | $0.00 |
DisclosureSEC source: 0000899243-16-034906 · doc4.xml · derivative · entry 1 Semigran Marc · CIK 0001691494 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2026-11-30 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 1, 2017, and the remaining shares subject to this option shall vest and become exercisable in 36 equal monthly installments thereafter. This option is subject to full acceleration of vesting with respect to all then-unvested shares in the event the reporting person's service relationship is terminated by the issuer or any successor without Cause (as defined in the issuer's 2015 Stock Option and Incentive Plan) within one year following the consummation of a Sale Event (as defined in the issuer's 2015 Stock Option and Incentive Plan). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.